301333 R&G PharmaStudies
- 38.64
- -1.16-2.91%
R&G PharmaStudies News
Nuo Si Ge (301333.SZ): has repurchased 1.50% of the shares.
On September 4, GeLongHui announced that as of August 31, 2024, the company has repurchased a total of 1,442,000 shares through a special securities account for centralized competitive trading, accounting for approximately 1.50% of the company's current total share capital of 96,000,000 shares. The highest fill price was 43.15 yuan/share, the lowest fill price was 35.06 yuan/share, and the total fill amount was 56.0627 million yuan (excluding transaction costs).
Norsk: 2024 Semi-Annual Report
Norsk: 2024 Semi-Annual Report Summary
Net income of 58.5105 million yuan in the first half of the year, a year-on-year decrease of 31.94%.
Guolonghui August 28th | Norsotech (301333.SZ) released its 2024 interim report, with revenue for the reporting period of 0.379 billion yuan, a year-on-year increase of 4.71%; net income attributable to shareholders of the listed company was 58.5105 million yuan, a year-on-year decrease of 31.94%; the net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was 46.4843 million yuan, a year-on-year decrease of 34.04%; and the basic earnings per share was 0.61 yuan.
R&G PharmaStudies Co., Ltd.'s (SZSE:301333) Intrinsic Value Is Potentially 35% Above Its Share Price
Norsger (301333.SZ): cumulative buyback of 1.33% of shares.
On August 1st, Gelonhui announced that as of July 31, 2024, the company has repurchased a total of 1,278,400 shares of the company through a repurchase dedicated securities account in a centralized bidding transaction, accounting for approximately 1.33% of the company's current total share capital of 96,000,000 shares. The highest fill price was 43.15 yuan/share, the lowest fill price was 35.06 yuan/share, and the total trading amount was 49,567,973.00 yuan (excluding transaction fees). The implementation of the above-mentioned repurchase is in compliance with relevant laws and regulations as well as the company's established repurchase plan.
Norske (301333.SZ) plans to launch an employee stock ownership plan in 2024.
Norris Greig (301333.SZ) has issued a draft of the 2024 employee stock ownership plan for participation by employees...
The shareholders of Nordisk (301333.SZ), Harmony Growth Phase II and Harmony Health did not reduce their shareholding at the end of the reduction period.
Northeast Securities (301333.SZ) announced that on July 22, 2024, the company received investment of the second phase of Harmonious Growth Fund and Harmonious ...
Norsgedge (301333.SZ): Has accumulated repurchased 1.28% of shares.
On July 19th, Gelonhui reported that up until July 19, 2024, Nosige (301333.SZ) had repurchased 1,228,300 shares of the company through a repurchase dedicated securities account using centralized bidding trading method, accounting for approximately 1.28% of the company's current total share capital of 96,000,000 shares. The highest fill price was 43.15 yuan/share, the lowest fill price was 35.06 yuan/share, and the total fill amount was 47.4204 million yuan (excluding transaction fees).
Why You Might Be Interested In R&G PharmaStudies Co., Ltd. (SZSE:301333) For Its Upcoming Dividend
Northeast Securities (301333.SZ) plans to spend 50-80 million yuan to buy back shares.
On July 1st, Gelonhui announced that North Gear (301333.SZ) plans to repurchase its shares for employee stock ownership plans or stock-based incentives. The total amount of funds for repurchasing shares ranges from RMB 50 million (including par value) to RMB 80 million (including par value). The repurchase price does not exceed RMB 58.00 per share (including par value). The implementation period for the repurchase of shares shall not exceed 12 months from the date of approval of the repurchase plan by the board of directors.
Norstec (301333.SZ) annual equity distribution in 2023: 2 yuan per 10 shares, registered on July 4th.
Norseldge (301333.SZ) announced that the company's annual equity distribution plan for 2023 is: based on the company's existing total share capital, a cash dividend of RMB 2 yuan for every 10 shares will be distributed to all shareholders (including taxes). The registration date for this equity distribution is July 4, 2024, and the ex-dividend date is July 5, 2024.
Nuo Sigge (301333.SZ): There is currently no research on combating HIV and no relevant cooperation with Gilead at present.
On June 24th, Gelonhui reported that Norseg (301333.SZ) stated on the investor interaction platform that the company is currently not conducting research on combating HIV and there is no relevant cooperation with Gilead.
R&G PharmaStudies Co., Ltd.'s (SZSE:301333) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Pacific Securities: The pharmaceutical industry is under short-term pressure, and future policies will be frequent or enhance the certainty of clinical CRO benefits
With the end of the Fed's interest rate hike cycle, gradual easing of liquidity is expected to bring about a recovery in investment and financing, and overseas demand will improve ahead of local demand; future innovative drug support policies may be introduced intensively, and clinical CRO benefits are highly certain.
Norske (301333.SZ): At this stage, the Biological Act has no impact on the company's business in the US
On May 16, GLONGHUI (301333.SZ) said on an interactive platform that the company's business in the US is mainly data management and statistical analysis services, and that at this stage, the biological law has no impact on the company's business in the US.
Statutory Profit Doesn't Reflect How Good R&G PharmaStudies' (SZSE:301333) Earnings Are
Northgate (301333.SZ) announced first-quarter results, net profit of 23.489 million yuan, a decrease of 19.95%
Northgate (301333.SZ) released its report for the first quarter of 2024. The company's revenue was 177 million...
Norske (301333.SZ): Harmonious Growth Phase II and Harmonious Health plan to reduce their total holdings by no more than 3%
Gelonghui (301333.SZ) announced that shareholders holding 4,800,000 shares of the company (accounting for 5.0000% of the company's total share capital) Harmonious Growth Phase II (Yiwu) Investment Center (“Harmonious Growth Phase II”) and shareholders holding 2,155,200 shares of the company (accounting for 2.2450% of the company's total share capital ratio), Zhuhai Harmonious Health Investment Fund (limited partnership) (“Harmonious Health”) plan to reduce their share holdings through bulk transactions and centralized bidding transactions. Proposed reduction of shareholding by 2,880,000, proposed reduction of holdings
R&G PharmaStudies Co., Ltd.'s (SZSE:301333) Market Cap Dropped CN¥422m Last Week; Individual Investors Who Hold 51% Were Hit as Were Institutions
Analysis
Price Target
No Data
No Data